U. of Copenhagen Sets up ProteinCenter with $109M Award
The Novo Nordisk Foundation has awarded the University of Copenhagen in Denmark KRO 600 million [$109 million] to build a center dedicated to protein research, the university said this week.
The center is expected to open next year. Matthias Mann, currently at the Max Planck Institute for Biochemistry in Martinsried, Germany, and Søren Brunak at the Technical University of Denmark in Lyngby will lead two of the five research teams at the center. The funding will be allocated over 10 years.
“By mapping the structure and function of proteins in the healthy human body, we can gain a much better understanding of what goes wrong when you get a disorder and how diseases can be treated more effectively, for instance, with tailored proteins as drugs,” said Ulla Wewer, dean of the faculty of health sciences at the University of Copenhagen.
Revs Rise in Single Digits at Bruker Daltonics, Up 16.5 Percent Company-wide
Bruker BioSciences reported single-digit revenue growth for its Daltonics division as the company posted overall revenue growth of 16.5 percent for its first quarter.
The company does not break out financials for its separate divisions, but in a conference call accompanying the release of its earnings, Frank Laukien, president and CEO, said that revenue for the Daltonics division housing Bruker’s mass specs and other proteomics tools and instruments rose in the single digits. New order bookings for Bruker Daltonics grew in the double digits, he said.
Bruker Optics also saw revenues improve in the single digits while the AXS division saw the biggest revenue growth, “north of 20 percent,” Laukien said.
Revenues company-wide grew to $110.5 million, up from $94.9 million a year ago. Net income reached $3.9 million, up 19 percent from $3.3 million during the year-ago period.
During the three months ended March 31, the company spent $13.6 million on R&D. As of March 31, Bruker had $55.7 million in cash and cash equivalents.
PE Q1 Revs Up 13 Percent, Profits Down 38 Percent, Opens New HQ
Revenues at PerkinElmer rose 13 percent in the first quarter, the company reported last week, while net income slid 38 percent.
Revenues for the quarter rose to $402.9 million from $355.5 million during the year-ago period. Revenues for its Life and Analytical Sciences division rose 14 percent to $299.5 million from $261.9 million a year ago.
For the three months ended April 1, PerkinElmer reported a net income of $14.7 million, down from $23.6 million from a year ago.
SG&A expenses rose to 12 percent to $101.8 million from $89.9 million the year before. The company spent $27.8 million on R&D during the quarter. As of April 1, PerkinElmer had $119.6 million in cash and cash equivalents.
This week, Perkin Elmer opened its new corporate headquarters and technology center in Waltham, Mass. The 115-000 square foot campus includes a research and development facility for drug discovery, cellular science, and diagnostics business.
Lumera Renews ISB Deal for Biomarker ID, Extends MUSC Protein Array Deal
Lumera and the Institute for Systems Biology announced this week they have extended their collaboration for use of Lumera’s ProteomicProcessor to identify biomarkers for drug toxicity and cancer.
Terms of the deal were not disclosed. The collaboration was originally forged in February 2005 and renewed in October 2006.
In a statement, Lumera said that ISB researchers have demonstrated a label-free assay to determine protein expression patterns with antibodies printed on Lumera’s nanoCapture-gold microarray and analyzed with the ProteomicProcessor.
Lumera also said this week it and the Medical University of South Carolina have extended a collaboration to develop an antibody array that will measure the levels and modifications of patient mitochondrial proteins.
Lumera will retain the rights to commercialize any jointly developed intellectual property. No other financial details of the deal were disclosed.
Lumera and MUSC originally signed a protein array collaboration deal in February 2006.
Matritech Revs up 17 Percent, Loss Widens 34 Percent
Matritech reported a 17 percent increase in revenues during the first quarter, bolstered by a 17 percent increase in its lead product, the NMP22 BladderChek test.
For the three months ended March 31, Matritech’s revenues rose to $3.4 million from $2.9 million a year ago. Its NMP22 BladderChek test posted sales of $2.8 million. The test accounted for 89 percent of sales in the NMP22 product line.
The company saw its loss widen to $4.1 million, a 34 percent increase from $3.1 million a year ago. The company spent $640,374 on R&D during the period and had cash and cash equivalents of $2.9 million as of March 31.
Eksigent Inks Deal with Seoul-based Interface
Eksigent announced this week it has reached a deal with Interface Engineering for the sales and service Eksigent’s NanoLC and ExpressLC products in South Korea. Based in Seoul, Interface is a division of Bio-Medical Science.
Interface offers comprehensive distribution of scientific and laboratory systems in South Korea, the companies said in a statement, including products for sample preparation, chemical analysis, and data management.
Terms of the deal were not revealed.
New Waters MS Lab Opens at Northeastern U
Waters and Northeastern University this week opened the Waters Mass Spectrometry Laboratory within the university’s Barnett Institute of Chemical and Biological Analysis.
The MS lab will be used to study protein shapes and characteristics “to provide pharmaceutical and biotechnology innovators with the tools necessary to develop new treatment options for some of the world’s deadliest diseases, like AIDS and cancer,” the company said in a statement.
The lab will be equipped with four Waters mass specs — the Q-Tof Premier XE; LCT Classic; LCT Premier XE; and the Q-Tof API US.
Strategic Diagnostics Says Antibodies Useful in HPA Study
Strategic Diagnostics said this week that antibodies generated by its Genomic Antibodies technology differentially stained cancer-associated proteins in patient tissue samples in studies conducted by the Human Protein Atlas in Sweden.
The antibody reagents specifically target selected cancer-associated proteins and were studied as part of HPA’s tissue-profiling program. They generated high-resolution immunohistochemistry images “across a side spectrum of normal and cancerous tissues,” Strategic Diagnostics said in a statement. For each antibody, 576 spots of human tissue from 360 individuals were treated and stained.
Sigma-Aldrich Declares Dividend
Sigma-Aldrich’s board this week declared a quarterly cash dividend of $.115 per share, payable on June 15 to shareholders of record on June 1.